Orphan Biosimilars: Developers See Big Prospects In Small Markets; Soliris Is One Target
Executive Summary
Using lessons learned from the first wave of biosimilar approvals – and citing high prices in the US – some developers are starting to 'think small' with biosimilars for rare disease markets. Alexion’s Soliris is a case in point.
You may also be interested in...
The Birth Of An Orphan Biosimilar Market
Hard-won experience from the first wave of broad-market biosimilars will inform development of "orphan biosimilars," but Navigant Consulting says that biopharmas entering this orphan market will face a unique set of challenges.
US FDA’s Inner Circle Takes Shape: Shah Seen As Potential Successor To Abernethy
Anand Shah returns to FDA as deputy commissioner; like Abernethy, he is an oncologist with a background in big data.
‘Real World’ Opioid Abuse Data On OxyContin Again Under Review At US FDA
Resubmission comes more than four years after Purdue pulled an sNDA seeking to demonstrate ‘real-world’ abuse prevention.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests: